SCHEMBL893618

SCHEMBL893618

CN(C(=O)OC(C)(C)C)C1CCN(c2nc(CNC(=O)[C@@H]3CCCN3S(=O)(=O)c3ccc(Cl)s3)cc(-c3ccc(C(F)(F)F)cc3)n2)C1

nearest known ligand 0.48

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 18/20 0.48
KCNQ1 P51787 1/20 0.37
MMP8 P22894 1/20 0.37
MMP12 P39900 1/20 0.37
MMP13 P45452 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL893206 0.92 TRPA1 (0.51) TRPA1KCNQ1MMP8MMP12MMP13
SCHEMBL10202092 0.91 TRPA1 (0.52) TRPA1KCNQ1MMP8MMP12MMP13
SCHEMBL893885 0.91 TRPA1 (0.52) TRPA1KCNQ1MMP8MMP12MMP13
SCHEMBL893542 0.91 TRPA1 (0.52) TRPA1KCNQ1MMP8MMP12MMP13
SCHEMBL894414 0.89 TRPA1 (0.51) TRPA1KCNQ1MMP8MMP12MMP13
SCHEMBL10201914 0.89 TRPA1 (0.48) TRPA1KCNQ1MMP8MMP12MMP13
SCHEMBL894006 0.89 TRPA1 (0.48) TRPA1KCNQ1MMP8MMP12MMP13
SCHEMBL893255 0.89 TRPA1 (0.48) TRPA1KCNQ1MMP8MMP12MMP13
SCHEMBL893665 0.89 TRPA1 (0.48) TRPA1KCNQ1MMP8MMP12MMP13
SCHEMBL894529 0.86 TRPA1 (0.52) TRPA1KCNQ1MMP8MMP12MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8614201-B2 Heterocyclic amides as modulators of TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2013-12-24 US claimed
US-20120083474-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2012-04-05 US claimed
WO-2010141805-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2010-12-09 WO claimed
US-8614201-B2 Heterocyclic amides as modulators of TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2013-12-24 US disclosed
US-20120083474-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2012-04-05 US disclosed
US-20120083474-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2012-04-05 US disclosed
WO-2010141805-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2010-12-09 WO disclosed
WO-2010141805-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 JANSSEN PHARMACEUTICA NV (BE) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120083474-A1 HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 TRPA1, TRPV1, TRPV2 TRPA1 1/4885KCNQ1 300/4885MMP8 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.